Targeting HER2: recent developments and future directions for breast cancer patients.

Overexpression of the HER2/neu oncogene (also known as c-erbB2) is a frequent molecular event in multiple human cancers, including breast and ovarian cancer. Patients with cancer that overexpress HER2/neu are associated with unfavorable prognosis, shorter relapse time, and low survival rate. Treatments that target HER2/neu expression in cancer cells have been shown to be useful strategies to significantly reverse the malignancy induced by HER2/neu overexpression. The humanized anti-HER2/neu antibody, trastuzumab (Herceptin; Genentech, Inc, South San Francisco, CA) has proven to be effective in clinical trials in patients with metastatic breast cancer. In addition, tyrosine kinase inhibitors such as emodin can also target the HER2/neu oncogenic activity. Emodin treatment inhibits HER2/neu tyrosine kinase activity and preferentially suppresses the transformation of HER2/neu-overexpressing breast cancer cells. Emodin also sensitizes HER2/neu-overexpressing cancer cells to chemotherapeutic agents, including cisplatin, doxorubicin, etoposide, and paclitaxel. Alternatively, HER2/neu overexpression can be repressed by attenuating the promoter activity of the HER2/neu gene. We have identified a number of potent transcriptional regulators, including the ets family member PEA3 and the adenovirus type 5 E1A, which are able to repress HER2/neu gene expression. Expression of these transcriptional regulators resulted in downregulation of HER2/neu promoter activity and reversed the transformed phenotype of the cancer cells in vitro. In vivo studies show that these HER2/neu repressors can act therapeutically as tumor suppressor genes for tumors that overexpress HER2/neu. These preclinical studies clearly indicate that transcriptional repressors that downregulate HER2/neu can be effective regimens for cancer treatment in a gene therapy format. More importantly, the tumor-free survival rate of treated animals is dramatically increased under nontoxic doses compared with untreated animals. A phase I clinical trial using E1A-liposome in breast and ovarian patients has recently been completed. Following treatment, we observed downregulation of the HER2/neu protein accompanied by E1A expression in both cancer and noncancer cells. Numbers of tumor cells in the pleural effusion or ascites were found to be dramatically reduced after treatment. Furthermore, apoptosis was strongly induced in the tumor cells. A phase II study has been started to further evaluate therapeutic efficacy and tumor suppression mechanisms of E1A. These studies show the clinical potential of targeting HER2/neu in cancer therapy.

[1]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[2]  M. Hung,et al.  Cell cycle-dependent regulation of p185neu: a relationship between disruption of this regulation and transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[4]  N. Nomura,et al.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. , 1988, Oncogene.

[5]  M. Hung,et al.  The retinoblastoma gene product suppresses neu oncogene-induced transformation via transcriptional repression of neu. , 1992, The Journal of biological chemistry.

[6]  L. Cantley,et al.  The erbB3 gene product is a receptor for heregulin. , 1994, The Journal of biological chemistry.

[7]  M. Hung,et al.  Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. , 1993, Cancer research.

[8]  M. Hung,et al.  Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. , 1993, Cancer research.

[9]  W. Xia,et al.  Safety studies of the intraperitoneal injection of E1A–liposome complex in mice , 1997, Gene Therapy.

[10]  M. Hung,et al.  Cloning and characterization of the mouse neu promoter. , 1992, Oncogene.

[11]  J. Rhim,et al.  Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. , 1989, Cancer research.

[12]  M. Hung,et al.  Overexpression of the c‐erbB‐2/neu–encoded p185 protein in primary lung cancer , 1992, Molecular carcinogenesis.

[13]  M. Kraus,et al.  Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.

[14]  A. Ullrich,et al.  Heregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. , 1995, The EMBO journal.

[15]  R. Sutherland,et al.  Expression of the PEA3 group of ETS‐related transcription factors in human breast‐cancer cells , 1997, International journal of cancer.

[16]  G. Nicolson,et al.  c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. , 1994, Cancer research.

[17]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Hung,et al.  Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. , 1991, Oncogene.

[19]  M. Hung,et al.  Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. , 1995, Oncogene.

[20]  L. Huang,et al.  Safety study and characterization of E1A–liposome complex gene-delivery protocol in an ovarian cancer model , 1998, Gene Therapy.

[21]  S. Korsmeyer,et al.  The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Hung,et al.  Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. Higashino,et al.  A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. , 1996, Oncogene.

[24]  J. Inazawa,et al.  ERM, a PEA3 Subfamily of Ets Transcription Factors, Can Cooperate with c-Jun (*) , 1995, The Journal of Biological Chemistry.

[25]  D. Johnston,et al.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Hung,et al.  Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. , 1995, Cancer research.

[27]  M. Hung,et al.  Identification and characterization of a novel enhancer for the rat neu promoter , 1991, Molecular and cellular biology.

[28]  M. Hung,et al.  Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  G. Hortobagyi,et al.  Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  G. Chinnadurai,et al.  p53-independent apoptotic and necrotic cell deaths induced by adenovirus infection: suppression by E1B 19K and Bcl-2 proteins. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[31]  M. Hung,et al.  Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo , 1998, Oncogene.

[32]  J. Hsuan,et al.  A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. , 1996, Oncogene.

[33]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[35]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[36]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[37]  M. Hung,et al.  Inhibition of Nuclear Factor-κB Activity Is Involved in E1A-mediated Sensitization of Radiation-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[38]  Joe Y. Chang,et al.  The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer* , 1997, Oncogene.

[39]  A. Gazdar,et al.  Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.

[40]  Craig Montell,et al.  Complete transformation by adenovirus 2 requires both E1A proteins , 1984, Cell.

[41]  S. Lowe,et al.  Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. , 1993, Genes & development.

[42]  E. Nabel,et al.  Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[44]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[45]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Slamon,et al.  Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.

[47]  J. Nevins,et al.  Adenovirus E1A-mediated negative control of genes activated during F9 differentiation , 1989, Molecular and cellular biology.

[48]  S Toikkanen,et al.  Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Bast,et al.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .

[50]  M. Hung,et al.  Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor* , 1997, The Journal of Biological Chemistry.

[51]  P. Branton,et al.  Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. , 1995, Oncogene.

[52]  N. Ibrahim,et al.  Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. , 1995, Journal of the National Cancer Institute.

[53]  G. Plowman,et al.  Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 , 1993, Nature.

[54]  D. Slamon,et al.  HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer , 1997, Stem cells.

[55]  G. V. van Muijen,et al.  Simultaneous suppression of progression marker genes in the highly malignant human melanoma cell line BLM after transfection with the adenovirus-5 E1A gene. , 1996, Biochemical and Biophysical Research Communications - BBRC.

[56]  Noah Craft,et al.  A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.

[57]  M. Hung,et al.  Axl-Gas6 Interaction Counteracts E1A-Mediated Cell Growth Suppression and Proapoptotic Activity , 1999, Molecular and Cellular Biology.

[58]  M. Hung,et al.  Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. , 1996, Oncogene.

[59]  R. Pozzatti,et al.  The E1a gene of adenovirus type 2 reduces the metastatic potential of ras-transformed rat embryo cells , 1988, Molecular and cellular biology.

[60]  B. Degnan,et al.  The ets multigene family is conserved throughout the Metazoa. , 1993, Nucleic acids research.

[61]  M. Hung,et al.  HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. , 1995, Oncogene.

[62]  J. Hassell,et al.  Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells. , 1992, Genes & development.

[63]  S. Miller,et al.  Mechanisms of deregulated her2/neu expression in breast-cancer cell-lines. , 1994, International journal of oncology.

[64]  D. Leprince,et al.  Evolution of the ets gene family. , 1993, Biochemical and biophysical research communications.

[65]  R. Weinberg,et al.  Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[66]  G. Hortobagyi,et al.  Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol , 1998, Oncogene.

[67]  M. Hung,et al.  The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis , 2000, Nature Medicine.

[68]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[69]  C. Hauser,et al.  Oncogenic Neu/ErbB-2 Increases Ets, AP-1, and NF-B-dependent Gene Expression, and Inhibiting Ets Activation Blocks Neu-mediated Cellular Transformation (*) , 1996, The Journal of Biological Chemistry.

[70]  S. McKnight,et al.  Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins. , 1992, Genes & development.

[71]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[72]  M. Hung,et al.  Involvement of Co-activator p300 in the Transcriptional Regulation of the HER-2/neu Gene* , 1997, The Journal of Biological Chemistry.

[73]  C. A. Carraway,et al.  Association of the Ras to Mitogen-activated Protein Kinase Signal Transduction Pathway with Microfilaments , 1999, The Journal of Biological Chemistry.

[74]  M. Klemsz,et al.  The ETS-domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence. , 1990, Genes & development.

[75]  P. Byrd,et al.  Differential transformation of primary human embryo retinal cells by adenovirus E1 regions and combinations of E1A + ras. , 1988, Oncogene.

[76]  M. Hung,et al.  E1A Sensitizes Cells to Tumor Necrosis Factor-induced Apoptosis through Inhibition of IκB Kinases and Nuclear Factor κB Activities* , 1999, The Journal of Biological Chemistry.

[77]  P. Nowell,et al.  Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. , 1990, Cancer research.

[78]  S. Lowe,et al.  p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.

[79]  A. Eb,et al.  Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells , 1983, Nature.

[80]  M. Hung,et al.  Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  S. Frisch,et al.  Adenovirus E1A represses protease gene expression and inhibits metastasis of human tumor cells. , 1990, Oncogene.

[82]  J. Roth,et al.  Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. , 1989, Cancer research.

[83]  Dihua Yu,et al.  Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. , 1997, Cancer research.

[84]  S. Frisch,et al.  Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. , 1995, Cancer research.

[85]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[86]  S. Frisch.  Antioncogenic effect of adenovirus E1A in human tumor cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Hung,et al.  Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185neu , 1997, Oncogene.

[88]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[89]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[90]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[91]  J. Taylor,et al.  A role for the ETS domain transcription factor PEA3 in myogenic differentiation , 1997, Molecular and cellular biology.

[92]  H. Hurst,et al.  A novel transcription factor, OB2‐1, is required for overexpression of the proto‐oncogene c‐erbB‐2 in mammary tumour lines. , 1993, The EMBO journal.

[93]  M. Hung,et al.  Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene , 1991, Molecular and cellular biology.

[94]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[95]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[96]  M. Hung,et al.  Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Dihua Yu,et al.  Heregulin β1-activated Phosphatidylinositol 3-Kinase Enhances Aggregation of MCF-7 Breast Cancer Cells Independent of Extracellular Signal-regulated Kinase , 1999 .

[98]  H. Ruley.  Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture , 1983, Nature.

[99]  Leaf Huang,et al.  Potentiation of cationic liposome-mediated gene delivery by polycations. , 1996, Biochemistry.

[100]  D. Denhardt.  Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. , 1996, Critical reviews in oncogenesis.

[101]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[102]  G. Nicolson,et al.  Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. , 1992, Oncogene.

[103]  R. Finn,et al.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells , 1997, Oncogene.

[104]  P. Tempst,et al.  Differentiation-stimulated Activity Binds an ETS-like, Essential Regulatory Element in the Human Promyelocytic defensin-1Promoter* , 1998, The Journal of Biological Chemistry.